<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36822800</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000822</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000822</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The aim of the study was to investigate whether the IRAK1/JAK2/Flt3 inhibitor pacritinib prevents disease development in the lupus-prone ABIN1[D485N] knock-in mouse.</AbstractText><AbstractText Label="METHODS">ABIN1[D485N] knock-in mice aged 8&#x2009;weeks were fed for 10 weeks on a diet containing pacritinib. Body weight was monitored, and serum collected at the end to measure pacritinib, autoantibody and immunoglobulin levels. Splenic immune cell populations were analysed, and the kidney, liver and lungs examined for pathology.</AbstractText><AbstractText Label="RESULTS">Pacritinib prevented multiple facets of the lupus phenotype in ABIN1[D485N] knock-in mice, including splenomegaly, expansion of splenic germinal centre B cells, follicular T helper cells, and neutrophils, elevated serum levels of double-stranded DNA antibodies and immunoglobulins, glomerular IgA and lung inflammation.</AbstractText><AbstractText Label="CONCLUSIONS">Pacritinib may be useful for the treatment of multiorgan inflammation in patients with lupus.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petrova</LastName><ForeName>Tsvetana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueras-Vadillo</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nanda</LastName><ForeName>Sambit K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scudamore</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Exepathology, Devon, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7632-9492</Identifier><AffiliationInfo><Affiliation>MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK p.cohen@dundee.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/R021406/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C561234">11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Lupus Nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>21</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36822800</ArticleId><ArticleId IdType="pmc">PMC9950973</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000822</ArticleId><ArticleId IdType="pii">10/1/e000822</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Han J-W, Zheng H-F, Cui Y, et al. . Genome-Wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009;41:1234&#x2013;7. 10.1038/ng.472</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.472</ArticleId><ArticleId IdType="pubmed">19838193</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong H-B, Gao S-T, Pu X-M, et al. . Association of rs610604 in TNFAIP3 and rs17728338 in TNIP1 gene polymorphisms with psoriasis susceptibility: a meta-analysis of case-control studies. BMC Med Genet 2020;21:103. 10.1186/s12881-020-01041-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12881-020-01041-x</ArticleId><ArticleId IdType="pmc">PMC7216328</ArticleId><ArticleId IdType="pubmed">32398022</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanda SK, Venigalla RKC, Ordureau A, et al. . Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J Exp Med 2011;208:1215&#x2013;28. 10.1084/jem.20102177</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20102177</ArticleId><ArticleId IdType="pmc">PMC3173241</ArticleId><ArticleId IdType="pubmed">21606507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanda SK, Petrova T, Marchesi F, et al. . Distinct signals and immune cells drive liver pathology and glomerulonephritis in ABIN1 [ D485N ] mice. Life Sci Alliance 2019;2:e201900533. 10.26508/lsa.201900533</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.201900533</ArticleId><ArticleId IdType="pmc">PMC6836709</ArticleId><ArticleId IdType="pubmed">31694920</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudhgaonkar S, Ranade S, Nagar J, et al. . Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity. J Immunol 2017;198:1308&#x2013;19. 10.4049/jimmunol.1600583</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600583</ArticleId><ArticleId IdType="pmc">PMC5253435</ArticleId><ArticleId IdType="pubmed">28003376</ArticleId></ArticleIdList></Reference><Reference><Citation>Celhar T, Lu HK, Benso L, et al. . Tlr7 protein expression in mild and severe lupus-prone models is regulated in a leukocyte, genetic, and IRAK4 dependent manner. Front Immunol 2019;10:1546. 10.3389/fimmu.2019.01546</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01546</ArticleId><ArticleId IdType="pmc">PMC6636428</ArticleId><ArticleId IdType="pubmed">31354711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Xu K, Leng R-X, et al. . Association of interleukin-1 receptor-associated kinase (IRAK1) gene polymorphisms (rs3027898, rs1059702) with systemic lupus erythematosus in a Chinese Han population. Inflamm Res 2013;62:555&#x2013;60. 10.1007/s00011-013-0607-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-013-0607-2</ArticleId><ArticleId IdType="pubmed">23435933</ArticleId></ArticleIdList></Reference><Reference><Citation>Raafat II, El Guindy N, Shahin RMH, et al. . Toll-Like receptor 7 gene single nucleotide polymorphisms and the risk for systemic lupus erythematosus: a case-control study. Z Rheumatol 2018;77:416&#x2013;20. 10.1007/s00393-017-0283-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-017-0283-7</ArticleId><ArticleId IdType="pubmed">28243744</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanda SK, Lopez-Pelaez M, Arthur JSC, et al. . Suppression of IRAK1 or IRAK4 catalytic activity, but not type 1 IFN signaling, prevents lupus nephritis in mice expressing a ubiquitin binding-defective mutant of ABIN1. J Immunol 2016;197:4266&#x2013;73. 10.4049/jimmunol.1600788</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600788</ArticleId><ArticleId IdType="pmc">PMC5114882</ArticleId><ArticleId IdType="pubmed">27807192</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstovsek S, Odenike O, Singer JW, et al. . Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol 2016;9:137. 10.1186/s13045-016-0367-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-016-0367-x</ArticleId><ArticleId IdType="pmc">PMC5146859</ArticleId><ArticleId IdType="pubmed">27931243</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrova T, Nanda SK, Scudamore C, et al. . Prevention and partial reversion of the lupus phenotype in ABIN1 [ D485N ] mice by an IRAK4 inhibitor. Lupus Sci Med 2021;8:e000573. 10.1136/lupus-2021-000573</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000573</ArticleId><ArticleId IdType="pmc">PMC8628323</ArticleId><ArticleId IdType="pubmed">34836923</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrova T, Bennett K, Nanda S, et al. . Why are the phenotypes of TRAF6 knock-in and TRAF6 knock-out mice so different? PLoS One 2022;17:e0263151. 10.1371/journal.pone.0263151</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263151</ArticleId><ArticleId IdType="pmc">PMC8843210</ArticleId><ArticleId IdType="pubmed">35157702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopf M, Herren S, Wiles MV, et al. . Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med 1998;188:1895&#x2013;906. 10.1084/jem.188.10.1895</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.188.10.1895</ArticleId><ArticleId IdType="pmc">PMC2212418</ArticleId><ArticleId IdType="pubmed">9815267</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376&#x2013;86. 10.1002/art.39962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents. Front Med (Lausanne) 2020;7:303. 10.3389/fmed.2020.00303</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00303</ArticleId><ArticleId IdType="pmc">PMC7338653</ArticleId><ArticleId IdType="pubmed">32695790</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>